Agonist agents of CD47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
Number of patents in Portfolio can not be more than 2000
United States of America
Stats
-
Apr 19, 2022
Grant Date -
May 9, 2019
app pub date -
May 10, 2017
filing date -
May 10, 2017
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to cyclic peptides mimetics of the C-terminal binding domain of TSP-1. The present invention also relates to the use of these cyclic peptides as agonists of CD47 and their ability to trigger programmed cell death (PCD). The present invention further relate to a pharmaceutical composition for use in the treatment of diseases associated with defects in PCD such as cancers and immunological disorders (including chronic inflammation) and comprising at least one cyclic peptide according to the invention.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully